spacer
home > epc > summer 2019 > overcoming the industry data crisis
PUBLICATIONS
European Pharmaceutical Contractor

Overcoming the Industry Data Crisis




The amount of data generated around the world is growing exponentially and at rates that are so great they are difficult to grasp. By one calculation, 90% of the world’s data have been generated over the last two years (1). To put it in terms used by the International Data Corporation in its estimates: by 2025, the global datasphere will reach 175 zettabytes − the equivalent of 175 trillion gigabytes (2).

With data from the newest technologies, applications, devices, and wearables all contributing, the sheer breadth of available information in clinical research is staggering, and its potential for contributing positively to modernisation is virtually limitless. The pharmaceutical industry has progressively accepted electronic data capture (EDC) as the standard practice for clinical trials. Overall, the adoption of EDC has resulted in some improvement across the industry − relative to antiquated paper processes − but EDC still largely relies on paper-based source documents (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

 
Ed Seguine, CEO at Clinical Ink, is passionate about creating solutions for problems caused by current clinical trial processes and technologies. With more than 20 years of experience as a clinical technology executive at Big Pharma and startup organisations, Ed, a thought leader on key initiatives including CDISC and eClinical Forum, often presents at industry events and publishes regularly on the benefits of next-generation eSource solutions. He earned a Master of Business Administration from Indiana University, Bloomington, US, and a Bachelor of Science in Finance from Brigham Young University, US.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement